AR083973A1 - Composiciones y metodos para el tratamiento en aplicaciones clinicas de amplio espectro, no diferenciadas o combinadas - Google Patents
Composiciones y metodos para el tratamiento en aplicaciones clinicas de amplio espectro, no diferenciadas o combinadasInfo
- Publication number
- AR083973A1 AR083973A1 ARP110104369A ARP110104369A AR083973A1 AR 083973 A1 AR083973 A1 AR 083973A1 AR P110104369 A ARP110104369 A AR P110104369A AR P110104369 A ARP110104369 A AR P110104369A AR 083973 A1 AR083973 A1 AR 083973A1
- Authority
- AR
- Argentina
- Prior art keywords
- coli
- helicobacter
- spp
- enterobacterium
- pathogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere composiciones y métodos mejorados para inmunización pasiva. En modalidades, se proporciona una composición que comprende una combinación sinergista de anticuerpos policlonales específicos en una matriz portadora. La descripción proporciona composiciones y métodos efectivos, económicos, para el tratamiento de diarrea e infecciones entéricas en aplicaciones clínicas de amplio-espectro, no diferenciadas o combinadas.Reivindicación 1: Una composición caracterizada porque comprende: a) una cantidad efectiva humana no neonato de al menos una molécula enlazante específica, o fragmento de la misma, obtenida de un animal y que específicamente se une a un antígeno, en donde la molécula enlazante específica se selecciona de una inmunoglobulina, anticuerpo, péptido, receptor de linfocito variable, receptor celular, factor de transferencia, y una mezcla de los mismos; y, b) una matriz portadora que comprende al menos dos componentes obtenidos de un animal no humano seleccionado del grupo que consiste de enzimas, lactoferrina, transferrina, inmunoglobulinas no específicas, citocinas, células blancas de la sangre, componentes del complemento, interferonas, y fibronectina, en donde al menos una molécula enlazante específica y al menos dos componentes de la matriz portadora se obtienen de animales diferentes. Reivindicación 4: La composición de conformidad con cualquiera de las reivindicaciones 1 a 3, caracterizada porque el antígeno comprende un patógeno, un patógeno relacionado con toxina, un patógeno relacionado con el elemento de adhesión, cepa indeseable, o una combinación de los mismos. Reivindicación 6: La composición de conformidad con la reivindicación 4, caracterizada porque el patógeno se selecciona del grupo que consiste de: Campylobacter jejuni, Salmonella, Salmonella enterica serovar Typhi, Shigella dystenteriae, Plesiomonas shigelloides, Escherichia coli, E. coli enteropatogénica, E. coli enterotoxigénica, E. coli enteroagregativa, E. coli enteroinvasiva, E. coli hemorrágica, Clostridium dificile, Yersinia enterocolitica, Vibrio cholerae O1, Vibrio O139, Non-O1 Vibrios, Vibrio parahaemolyticus, Aeromonas hydrophila, Clostridium perfringens, Helicobacter enterohepática, Helícobacter pylori, Staphylococcus aureus, Klebsiella, Gardnerella spp., Neisseria gonorrhoeae, Chlamydiaceae trachomatis, Mycoplasma spp., Campylobacter jejuni, Tríchomonas vaginalis, virus del herpes tipo 1, virus del herpes tipo 2, Candida albícans, Candida glabrata, Candida tropicalis, Candida parapsilosis y Candida krusei, Streptococcus spp. Grupo A, rotavirus, coronavirus, norovirus, calicivirus, adenovirus entérico, citomegalovirus, astrovirus, S. pneumoniae, H. influenzae, Neisseria gonorrhoeae, virus del herpes zoster, Fusarium spp., y Acanthamoeba spp..
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41666710P | 2010-11-23 | 2010-11-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083973A1 true AR083973A1 (es) | 2013-04-10 |
Family
ID=46146180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110104369A AR083973A1 (es) | 2010-11-23 | 2011-11-23 | Composiciones y metodos para el tratamiento en aplicaciones clinicas de amplio espectro, no diferenciadas o combinadas |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US9701735B2 (es) |
| EP (2) | EP2643017B1 (es) |
| JP (2) | JP6121907B2 (es) |
| KR (2) | KR20140043303A (es) |
| CN (2) | CN105012950A (es) |
| AP (1) | AP2013006940A0 (es) |
| AR (1) | AR083973A1 (es) |
| AU (3) | AU2011332053B2 (es) |
| BR (1) | BR112013012594A2 (es) |
| CA (1) | CA2818827C (es) |
| CL (1) | CL2013001469A1 (es) |
| CO (1) | CO6791606A2 (es) |
| DK (1) | DK2643017T3 (es) |
| EA (1) | EA034057B1 (es) |
| ES (1) | ES2742734T3 (es) |
| HK (1) | HK1216616A1 (es) |
| IL (2) | IL226475A0 (es) |
| MA (1) | MA34753B1 (es) |
| MX (2) | MX340019B (es) |
| MY (1) | MY164281A (es) |
| NZ (2) | NZ709245A (es) |
| PE (1) | PE20141173A1 (es) |
| PH (2) | PH12013501040A1 (es) |
| PT (1) | PT2643017T (es) |
| SG (2) | SG190384A1 (es) |
| TW (2) | TWI656881B (es) |
| UA (1) | UA115524C2 (es) |
| WO (1) | WO2012071346A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140017257A1 (en) * | 2012-07-11 | 2014-01-16 | Xi Jiang | IgY From Norovirus P Particles And Their Derivatives |
| US9458230B2 (en) * | 2013-01-04 | 2016-10-04 | Wisconsin Alumni Research Foundation | Secretory IGA compositions, methods of making and methods of use thereof |
| US9321803B2 (en) | 2013-07-12 | 2016-04-26 | Children's Hospital Medical Center | Compositions and methods for inhibiting norovirus infection |
| CN104829713A (zh) * | 2014-05-27 | 2015-08-12 | 青岛大学附属医院 | 特异性抗镰刀菌感染的鸡卵黄抗体的制备和应用 |
| EP3207055A1 (en) * | 2014-10-15 | 2017-08-23 | Xenothera | Composition with reduced immunogenicity |
| US11168127B1 (en) * | 2015-12-01 | 2021-11-09 | Camas Incorporated | Pathogen specific avian antibodies in the neonatal mammal |
| US10632158B2 (en) | 2016-06-23 | 2020-04-28 | IgY Nutrition | Use of a hyperimmune egg product to prevent and treat dysbiosis |
| EP3490602A4 (en) * | 2016-08-01 | 2020-03-25 | Scaled Microbiomics, LLC | SYSTEMS AND METHODS FOR MODIFYING THE MICROBIOME TO REDUCE THE RISK OF ILLNESS AND MANIFESTATIONS OF ILLNESS |
| CN110381991B (zh) | 2017-03-28 | 2024-04-09 | 儿童医院医学中心 | 诺如病毒s颗粒类疫苗及其制备和使用方法 |
| WO2019087372A1 (ja) * | 2017-11-02 | 2019-05-09 | オーストリッチファーマ株式会社 | 細菌感染症用ダチョウ抗体 |
| AU2018379996A1 (en) | 2017-12-05 | 2020-06-25 | BioPlx, Inc. | Methods and compositions to prevent microbial infection |
| CN109908344A (zh) * | 2017-12-12 | 2019-06-21 | 广州汇高生物科技有限公司 | 一种用于治疗溃疡性结肠炎的药物组合物及其制备方法 |
| EP3861020A4 (en) * | 2018-10-03 | 2022-07-13 | Anubis Bio Corporation | Composition and methods for treating acute diarrhea and enteric infections in animals |
| WO2020132296A1 (en) * | 2018-12-20 | 2020-06-25 | Pantheryx, Inc. | Medical nutrition product composition for acute diarrhea |
| US12263192B2 (en) | 2019-02-26 | 2025-04-01 | Pantheryx, Inc. | Compositions for management of disorders of the gastrointestinal tract |
| WO2020237023A1 (en) * | 2019-05-21 | 2020-11-26 | Scaled Microbiomics, Llc | Formulations for altering microbiome to reduce risks of hereditary and spontaneous colorectal cancers |
| US12194096B2 (en) | 2019-10-31 | 2025-01-14 | Stevens Law Group | Composition and methods for preventing and treating African swine fever in wild and domestic swine |
| US20210252149A1 (en) * | 2020-02-19 | 2021-08-19 | Anubis Bio Corporation | Composition and Methods for Treating Infectious Agents Using Pathogen-specific Antibodies |
| EP4125965A4 (en) * | 2020-04-03 | 2024-04-24 | University of Utah Research Foundation | METHOD OF TREATMENT OF LUNG DISEASE WITH CELLULAR AMNIOTIC FLUID |
| WO2021205408A1 (en) * | 2020-04-10 | 2021-10-14 | Igy Immune Technologies And Life Sciences Inc. | Igy immunoglobulins targeting coronavirus, methods of preparing same, and methods of using same |
| AU2021256984A1 (en) * | 2020-04-14 | 2022-12-01 | Scaled Microbiomics, Llc | Treating or preventing travelers diarrhea |
| CN111803628B (zh) * | 2020-07-24 | 2021-05-14 | 尤丽康（江苏）生物医药有限公司 | 一种抗幽门螺杆菌复合制剂 |
| WO2022103871A1 (en) * | 2020-11-10 | 2022-05-19 | Wyomingv Immune, Inc. | Therapeutic compositions for the treatment of covid-19 |
| AU2022258701A1 (en) * | 2021-04-16 | 2023-10-26 | Prodigy Biotech | Hyperimmunized egg product for treating or preventing alcoholic liver disease and graft-versus-host disease |
| US11319382B1 (en) | 2021-06-28 | 2022-05-03 | King Abdulaziz University | Methods for producing and using IgY antibodies targeting the middle east respiratory syndrome coronavirus spike protein to treat or prevent MERS-CoV infection |
| TW202444746A (zh) * | 2023-05-03 | 2024-11-16 | 財團法人國家衛生研究院 | 治療及／或預防諾羅病毒感染之免疫球蛋白ｙ組合物 |
| WO2024232765A1 (en) * | 2023-05-10 | 2024-11-14 | Koru Biotech Solutions Limited | Therapeutic agents and compositions and related methods |
| JP7479620B1 (ja) * | 2023-09-19 | 2024-05-09 | 有限会社バイオメディカルリサーチグループ | リポ多糖、リポ多糖製造方法及びリポ多糖配合物 |
| WO2025259740A1 (en) * | 2024-06-12 | 2025-12-18 | Elanco Us Inc. | Lysozyme compositions and methods thereof |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US4550019A (en) | 1978-03-22 | 1985-10-29 | South Africa Inventions Development Corporation | Manufacture and use of fowl egg antibodies |
| US4377569A (en) | 1980-01-21 | 1983-03-22 | Plymate Robert R | Method of treating animals to resist infectious diseases |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4341763A (en) * | 1981-03-10 | 1982-07-27 | Smithkline-Rit | Methods of vaccinating humans against rotavirus infection |
| NZ201698A (en) | 1981-08-31 | 1985-12-13 | S L Gaffin | Composition of antibodies specific to endotoxins |
| US4748018A (en) | 1984-02-07 | 1988-05-31 | Stolle Research & Development Corp. | Method of passive immunization of mammals using avian antibody |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4816563A (en) | 1983-11-25 | 1989-03-28 | Amtron, Inc. | Process for obtaining transfer factor from colostrum, transfer factor so obtained and use thereof |
| JPS60123428A (ja) | 1983-12-05 | 1985-07-02 | Green Cross Corp:The | 下痢症治療剤 |
| US5198213A (en) | 1985-04-15 | 1993-03-30 | Protein Technology, Inc. | Method of disease treatment utilizing an immunologically whey fraction |
| EP0225254B1 (en) | 1985-11-25 | 1994-03-16 | Ghen Corporation | Specific antibody-containing substance from eggs and method of production and use thereof |
| IT1204777B (it) | 1986-02-04 | 1989-03-10 | Crinos Industria Farmaco | Composizione per la preparazione estemporanea di formulazioni per applicazioni topiche per uso farmaceutico e cosmetico |
| US5017372A (en) | 1986-04-14 | 1991-05-21 | Medicis Corporation | Method of producing antibody-fortified dry whey |
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| DE58904683D1 (de) | 1988-04-19 | 1993-07-22 | Biotest Pharma Gmbh | Praeparat mit antikoerperaktivitaet und breitem wirkungsspektrum, daraus bestehende oder diese enthaltende mittel und deren verwendung zur behandlung von bakteriell oder toxin-bedingten erkrankungen und zur bekaempfung von protozoen. |
| US5601823A (en) | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
| US5719267A (en) | 1989-10-31 | 1998-02-17 | Ophidian Pharmaceuticals Inc. | Clostridial toxin disease therapy |
| DE69127694T2 (de) | 1990-07-02 | 1998-04-02 | National Jewish Center For Immunology And Respiratory Medicine, Denver, Col. | Herstellung und verwendung von transfer-faktor |
| US5258178A (en) | 1990-07-30 | 1993-11-02 | Abbott Laboratories | Method and product for the treatment of gastric disease |
| US5753228A (en) | 1992-08-25 | 1998-05-19 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Method of treating parasitosis by the enteral administration of hyperimmune hen egg yolk antibodies |
| US5367054A (en) | 1993-04-12 | 1994-11-22 | Stolle Research & Development Corp. | Large-scale purification of egg immunoglobulin |
| US5585098A (en) | 1993-11-23 | 1996-12-17 | Ovimmune, Inc. | Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants |
| US5876735A (en) | 1994-04-22 | 1999-03-02 | Corixa Corporation | Methods for enhancement of protective immune responses |
| JP2001501622A (ja) | 1996-10-02 | 2001-02-06 | オビミュン インコーポレイテッド | 病気を治療するための鶏卵黄抗体の経口投与 |
| SE9701026D0 (sv) | 1997-03-20 | 1997-03-20 | Immun System Ims Ab | use of avian antibodies |
| JPH10265393A (ja) | 1997-03-25 | 1998-10-06 | Natl Fedelation Of Agricult Coop Assoc | 豚流行性下痢の予防治療剤 |
| JP3430853B2 (ja) | 1997-04-11 | 2003-07-28 | 株式会社ゲン・コーポレーション | 胃炎、胃潰瘍および十二指腸潰瘍の予防剤並びに治療剤 |
| CA2291487A1 (en) | 1997-05-29 | 1998-12-03 | New Zealand Pastoral Agriculture Research Institute Limited | Processes for production of immunoglobulin a in milk |
| US5846569A (en) | 1997-06-20 | 1998-12-08 | Creative Labs, Inc. | Colostrum supplement |
| IE970541A1 (en) | 1997-07-25 | 1999-01-27 | Michael Anthony Folan | Maternal immune secretions and their use in the treatment and/or prophylaxis of the buccal cavity |
| CZ287956B6 (cs) | 1997-11-04 | 2001-03-14 | Medipharm Cz, S. R. O. | Perorální přípravek k prevenci a léčbě parvovirózy psů |
| CN1290580C (zh) * | 1998-04-01 | 2006-12-20 | 中德联合研究院 | 抗轮状病毒鸡卵黄免疫球蛋白产品 |
| EP1075190B1 (en) | 1998-04-29 | 2005-06-22 | Fonnelop, Kare | A process for the preparation of colostrum |
| EP1087788A1 (fr) | 1998-06-26 | 2001-04-04 | Aventis Pasteur | Immunisation a ciblage mucosal |
| US6258383B1 (en) | 1998-08-14 | 2001-07-10 | Lactoferrin Products Company | Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format |
| IL142261A0 (en) | 1998-10-01 | 2002-03-10 | Canadian Inovatech Inc | Egg concentrate product |
| US6379676B2 (en) | 1999-03-10 | 2002-04-30 | Anitox Corporation | Enhancing immune response in animals |
| US6348223B1 (en) | 1999-06-29 | 2002-02-19 | Rose Acre Farms, Inc. | Milk replacer composition and method |
| AU2001249388A1 (en) | 2000-03-24 | 2001-10-08 | Trouw Nutrition Usa | Combination of plasma and hyperimmunized products for increased performance |
| CN1218751C (zh) * | 2000-08-31 | 2005-09-14 | 北京好友巡天生物技术有限责任公司 | 二元活性抗体制剂及其制备方法 |
| US20020044942A1 (en) | 2000-09-18 | 2002-04-18 | Chisolm Biological Laboratory, Llc | Transfer factor composition and process for producing same |
| US6468534B1 (en) | 2000-09-21 | 2002-10-22 | 4Life Research, Lc | Methods for obtaining transfer factor from avian sources, compositions including avian-generated transfer factor, and methods of use |
| CN1411378A (zh) | 2001-01-05 | 2003-04-16 | 鸡蛋高新技术有限公司 | 含有抗病原菌特异抗体(IgY)的鸡蛋及含有该IgY的酸乳和冰淇淋的生产方法 |
| US7244427B2 (en) | 2001-01-30 | 2007-07-17 | The Lauridsen Group Incorporated | Isolated bovine IgG heavy chain protein and its use as an antimicrobial |
| US6939954B2 (en) | 2001-01-30 | 2005-09-06 | The Lauridsen Group Incorporated | Isolated bovine lgG heavy chain protein and its use as an antimicrobial |
| CA2339436A1 (fr) | 2001-03-15 | 2002-09-15 | Josee Harel | Production d'anticorps contre les facteurs de virulence associes aux souches d'escherichia coli aeec, et leur utilisation |
| US6932967B2 (en) | 2001-03-22 | 2005-08-23 | Michael R. Simon | Human medical treatment by aerosol inhalation of immunoglobulin A |
| TW200402303A (en) | 2002-03-21 | 2004-02-16 | Anadis Ltd | Composition containing bioactive materials and method of preparation and treatment |
| CA2486801A1 (en) | 2002-05-21 | 2003-11-27 | Anadis Ltd | Method of prophylaxis of infection |
| US7815943B2 (en) | 2002-08-22 | 2010-10-19 | 4Life Research, Lc | Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition |
| JP4556407B2 (ja) | 2002-10-04 | 2010-10-06 | 住友金属鉱山株式会社 | 酸化物透明電極膜とその製造方法、透明導電性基材、太陽電池および光検出素子 |
| SE0203265D0 (sv) | 2002-11-06 | 2002-11-06 | Coloplus Ab | A feed or food product composition |
| DK1587539T3 (da) | 2003-01-16 | 2010-11-08 | Pedersen Medical As | Antimikrobielt præparat til lokal anvendelse på slimhindemembraner og hud |
| SE0300213D0 (sv) | 2003-01-30 | 2003-01-30 | Immun System Uppsala I M S Ab | Use of avian antibodies |
| AU2003901008A0 (en) | 2003-03-04 | 2003-03-20 | Anadis Ltd | Composition for the treatment and prevention of bacterial infections |
| US6866868B1 (en) | 2003-09-15 | 2005-03-15 | 4Life Research, Lc | Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions |
| EP1723951A1 (en) | 2005-04-21 | 2006-11-22 | N.V. Nutricia | Nutritional supplement with oligosaccharides for a category of HIV patients |
| PT1629850E (pt) | 2004-08-24 | 2007-08-14 | Nutricia Nv | Composição nutricional que compreende a administração de oligossacarídeos indigeríveis |
| NZ554142A (en) | 2004-10-06 | 2009-12-24 | Agri Biotech Pty Ltd | Antibody production method comprising inserting antigen releasing device into mammal so antibodies are released into its milk |
| BRPI0516681A (pt) | 2004-11-25 | 2008-09-16 | Unilever Nv | sistema de entrega de anticorpos ao trato gastrointestinal, vetor de expressão, microorganismos transformados, método de entrega de anticorpos, imunoglobulinas de cadeia pesada e seu uso, produto alimentìcio e seu método de fabricação e utensìlio de distribuição |
| WO2006057551A1 (en) | 2004-11-26 | 2006-06-01 | N.V. Nutricia | Infant nutrition with protease inhibitor |
| US10471100B2 (en) | 2006-09-29 | 2019-11-12 | 4Life Patents, Llc | Nanofraction immune modulators, preparations and compositions including the same, and associated methods |
| MX2008002222A (es) | 2005-08-19 | 2008-03-25 | Unilever Nv | Productos alimenticios que comprende microorganismos probioticos y anticuerpos. |
| US20070264264A1 (en) * | 2005-08-30 | 2007-11-15 | La Belle Associates, Inc. | Method and composition for conferring immunity in mammals |
| CA2521156A1 (en) | 2005-09-16 | 2007-03-16 | John Hare | Antibodies as growth promoting agents |
| CN1965665A (zh) * | 2005-11-16 | 2007-05-23 | 雅臣药业集团（远东）有限公司 | IgY抗体免疫奶或奶粉的制备方法 |
| AU2007281934B2 (en) * | 2006-01-18 | 2012-11-15 | University Of Chicago | Compositions and methods related to Staphylococcal bacterium proteins |
| WO2007108541A1 (ja) | 2006-03-23 | 2007-09-27 | Senju Pharmaceutical Co., Ltd. | キサンタンガムおよびブドウ糖を含有する眼科用組成物 |
| US20090053197A1 (en) | 2006-06-14 | 2009-02-26 | Ramaekers Joseph C | Transfer Factor Compositions and Methods |
| US20080031903A1 (en) | 2006-07-27 | 2008-02-07 | Andrea Gambotto | Method of treating ocular infections |
| AU2007291891B2 (en) | 2006-08-31 | 2013-10-31 | A.C.N. 135 493 391 Pty Ltd | Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions |
| WO2009020748A2 (en) | 2007-07-16 | 2009-02-12 | Avaxia Biologics, Inc. | Antibody therapy for modulating function of intestinal receptors |
| CN101790540A (zh) | 2007-08-30 | 2010-07-28 | 本特·阿格鲁普 | 局部施用鸡卵黄免疫球蛋白(IgY)以治疗和预防真菌感染 |
| CA2734139C (en) | 2007-10-02 | 2019-12-24 | Avaxia Biologics, Inc. | Antibody therapy for use in the digestive tract |
| EP2058001A1 (en) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Enhancement of immunogenicity of antigens |
| EP3231816A1 (en) | 2008-03-13 | 2017-10-18 | Immuron Limited | Bovine colostrum comprising anti-insulin antibodies for treating diabetes, non alcoholic fatty liver disease, hyperlipidemia or atherosclerosis. |
| CA2720210A1 (en) | 2008-04-18 | 2009-10-22 | Unilever Plc | Compositions comprising antibodies or antibody fragments |
| WO2010044095A2 (en) | 2008-09-04 | 2010-04-22 | Pawan Saharan | Novel immunologically active peptide fragments of a proline- rich polypeptide isolated from mammalian colostrums for treatment of viral and non-viral diseases or diseased conditions |
| JP5740390B2 (ja) | 2009-04-27 | 2015-06-24 | イミューロン リミテッドＩｍｍｕｒｏｎ Ｌｉｍｉｔｅｄ | 病的障害の治療および／または予防において使用するための抗ｌｐｓ強化免疫グロブリン製剤 |
| US8211435B2 (en) * | 2009-06-09 | 2012-07-03 | Hamid Reza Rahmani | Calf biologic anti-scour supplement (CBAS) |
| US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
| US20110129479A1 (en) | 2009-12-02 | 2011-06-02 | Tobin Monte B | Immunogen selection directed in immunoglobulin packages in plasma and colostrum and method of making and using same |
-
2011
- 2011-11-21 AP AP2013006940A patent/AP2013006940A0/xx unknown
- 2011-11-21 KR KR1020137016241A patent/KR20140043303A/ko not_active Ceased
- 2011-11-21 EP EP11843171.7A patent/EP2643017B1/en active Active
- 2011-11-21 NZ NZ709245A patent/NZ709245A/en not_active IP Right Cessation
- 2011-11-21 KR KR1020187037153A patent/KR102037885B1/ko not_active Expired - Fee Related
- 2011-11-21 ES ES11843171T patent/ES2742734T3/es active Active
- 2011-11-21 EP EP18183215.5A patent/EP3424531A1/en not_active Withdrawn
- 2011-11-21 SG SG2013039813A patent/SG190384A1/en unknown
- 2011-11-21 MY MYPI2013700858A patent/MY164281A/en unknown
- 2011-11-21 NZ NZ612299A patent/NZ612299A/en not_active IP Right Cessation
- 2011-11-21 JP JP2013540999A patent/JP6121907B2/ja active Active
- 2011-11-21 MX MX2013005704A patent/MX340019B/es active IP Right Grant
- 2011-11-21 CA CA2818827A patent/CA2818827C/en active Active
- 2011-11-21 EA EA201370127A patent/EA034057B1/ru not_active IP Right Cessation
- 2011-11-21 UA UAA201307932A patent/UA115524C2/uk unknown
- 2011-11-21 PT PT11843171T patent/PT2643017T/pt unknown
- 2011-11-21 DK DK11843171.7T patent/DK2643017T3/da active
- 2011-11-21 MX MX2016007912A patent/MX355905B/es unknown
- 2011-11-21 WO PCT/US2011/061708 patent/WO2012071346A1/en not_active Ceased
- 2011-11-21 AU AU2011332053A patent/AU2011332053B2/en active Active
- 2011-11-21 BR BR112013012594A patent/BR112013012594A2/pt not_active Application Discontinuation
- 2011-11-21 SG SG10201509584UA patent/SG10201509584UA/en unknown
- 2011-11-21 PH PH1/2013/501040A patent/PH12013501040A1/en unknown
- 2011-11-21 CN CN201510309672.5A patent/CN105012950A/zh active Pending
- 2011-11-21 CN CN201180065699.4A patent/CN103533958B/zh active Active
- 2011-11-21 PE PE2013001246A patent/PE20141173A1/es active IP Right Grant
- 2011-11-22 US US13/302,836 patent/US9701735B2/en active Active
- 2011-11-23 TW TW105114213A patent/TWI656881B/zh not_active IP Right Cessation
- 2011-11-23 TW TW100142991A patent/TWI539964B/zh not_active IP Right Cessation
- 2011-11-23 AR ARP110104369A patent/AR083973A1/es unknown
-
2013
- 2013-05-20 IL IL226475A patent/IL226475A0/en active IP Right Grant
- 2013-05-23 CL CL2013001469A patent/CL2013001469A1/es unknown
- 2013-06-21 MA MA36032A patent/MA34753B1/fr unknown
- 2013-06-21 CO CO13148236A patent/CO6791606A2/es not_active Application Discontinuation
-
2016
- 2016-03-15 AU AU2016201651A patent/AU2016201651B2/en not_active Ceased
- 2016-04-22 HK HK16104673.8A patent/HK1216616A1/zh unknown
- 2016-11-07 JP JP2016217090A patent/JP2017075150A/ja active Pending
-
2017
- 2017-06-07 US US15/616,724 patent/US10611828B2/en active Active
-
2018
- 2018-05-17 AU AU2018203497A patent/AU2018203497B2/en not_active Ceased
- 2018-08-23 IL IL26133818A patent/IL261338B/en active IP Right Grant
- 2018-09-05 PH PH12018501891A patent/PH12018501891A1/en unknown
-
2020
- 2020-02-26 US US16/801,696 patent/US20200299360A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR083973A1 (es) | Composiciones y metodos para el tratamiento en aplicaciones clinicas de amplio espectro, no diferenciadas o combinadas | |
| JP7579291B2 (ja) | 多重特異性抗原結合分子およびその使用 | |
| US12297257B2 (en) | Multispecific antigen-binding molecules and uses thereof | |
| Butler et al. | Immunoglobulins, antibody repertoire and B cell development | |
| RU2487723C2 (ru) | Химерные и гуманизированные антитела к cd44, которые опосредствуют цитотоксичность в отношении раковых клеток | |
| UY37325A (es) | Anticuerpos monoclonales que se enlazan a tim3 para estimular respuestas inmunitarias y composiciones que los contienen | |
| BR112014010532A2 (pt) | anticorpo e métodos para inibição seletiva de respostas de célula-t | |
| AR111362A1 (es) | Anticuerpos anti-ilt4 y fragmentos de unión a antígeno | |
| PE20110225A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| RU2011143905A (ru) | ПОЛИСПЕЦИФИЧНЫЕ АНТИТЕЛА, ВКЛЮЧАЮЩИЕ АНТИТЕЛА ПОЛНОЙ ДЛИНЫ И ОДНОЦЕПОЧЕЧНЫЕ ФРАГМЕНТЫ Fab | |
| ES2502541T3 (es) | Medicamento que incluye una composición de anticuerpos unida específicamente al receptor 4 de quimiocina CC humana (CCR4) | |
| Bergström et al. | IgG suppresses antibody responses in mice lacking C1q, C3, complement receptors 1 and 2, or IgG Fc-receptors | |
| Wang et al. | Characterization of a natural mouse monoclonal antibody recognizing epitopes shared by oxidized low-density lipoprotein and chaperonin 60 of Aggregatibacter actinomycetemcomitans | |
| Parma et al. | Antibodies anti-Shiga toxin 2 B subunit from chicken egg yolk: isolation, purification and neutralization efficacy | |
| Corthésy et al. | Oral passive immunization with plasma-derived polyreactive secretory-like IgA/M partially protects mice against experimental salmonellosis | |
| Sahagun-Ruiz et al. | Reduction of enterotoxin induced fluid accumulation in ileal loops of neonatal calves with anti-F5 fimbriae recombinant antibody | |
| Kondo et al. | Preliminary characterization of pathogen-detection activities of serum antibodies from the banded houndshark Triakis scyllium | |
| CN103937898B (zh) | 单核细胞增生性李斯特菌免疫pcr检测试剂盒 | |
| CN103866033B (zh) | 金黄色葡萄球菌免疫pcr检测试剂盒 | |
| AR133720A1 (es) | ANTICUERPOS BIESPECÍFICOS QUE UNEN CD3 Y EL GANGLIÓSIDO NGcGM3 | |
| Liu et al. | CLL Stereotyped Subset# 4 Igs Acquire Binding to Viable B Lymphocyte Surfaces By Somatic Mutations, Isotype Class Switching, and with the Prerequisite of IG Self-Association | |
| CN103119066A (zh) | 具有抑制TGF-β受体活化的活性的化合物、该化合物的筛选方法、以及用于预防或治疗由丙型肝炎病毒引起的疾病的组合物 | |
| Akhi | Chunguang Wang, Jari Kankaanpää, Outi Kummu, S. Pauliina Turunen | |
| JPWO2019197609A5 (es) | ||
| TH1701001044A (th) | แอนติบอดี และ ไคมีริกแอนติเจนรีเซปเตอร์ที่จำเพาะสำหรับ cd19 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |